Munich Re logo
Munich Re HealthTech
Celent’s independent briefing note on SMAART
© Getty

Celent’s independent briefing note on SMAART

2020/02/05

    alt txt

    properties.trackTitle

    properties.trackSubtitle

    We are more than honored that Celent, the expert research firm, a division of Oliver Wyman, has prepared an independent briefing note on our Sophisticated Monitoring and Analysis of Risk Tool (SMAART), an out-of-the-box business monitoring and performance improvement solution.

    Constantly monitoring technical ratios and other metrics in this business is a “must” not only to identify rooms for improvements but also to anticipate negative outcomes. SMAART helps health insurers to track key performance indicators at various levels but more precisely it provides deep insights on the evolution of their technical ratios. With today’s data and technology, it is possible to obtain granular information on various dimensions and SMAART allows deep analysis of specific business operations including group policy renewals and network analysis for instance.

    Making informed decisions based on reliable data on technical insurance performance is a challenge for decision-makers.

    Download this briefing note by Celent and learn more about the full functionality of SMAART and how it can support the daily decision making in health insurance.
    Please enter your full name.
    Please enter your email.
    Please enter your company.
    Please enter your job title.
    By selecting the check box, you consent that your data submitted to MR HealthTech Ltd. through your application will be processed on the basis of the provisions of the current versions of the EU General Data Protection Regulation (GDPR) and the relevant Greek legislation. By providing your consent, you have the right to revoke it at any time in the future. For more information, please visit the GDPR section and Privacy Notice section on our website.
    Download
    Your message has been sent to MR HealthTech.